Sales Jessica M, Escoffery Cam, Hussen Sophia A, Haddad Lisa B, Phillips Ashley, Filipowicz Teresa, Sanchez Maria, McCumber Micah, Rupp Betty, Kwiatkowski Evan, Psioda Matthew A, Sheth Anandi N
Department of Behavioral Sciences and Health Education, Rollins School of Public Health, Emory University, Atlanta, GA, United States.
Department of Gynecology and Obstetrics, School of Medicine, Emory University, Atlanta, GA, United States.
JMIR Res Protoc. 2019 May 6;8(6):e12774. doi: 10.2196/12774.
BACKGROUND: Black adolescent and young adult women (AYAW) in the Southern United States are disproportionately affected by HIV. Pre-exposure prophylaxis (PrEP) is an effective, scalable, individual-controlled HIV prevention strategy that is grossly underutilized among women of all ages and requires innovative delivery approaches to optimize its benefit. Anchoring PrEP delivery to health services that AYAW already trust, access routinely, and deem useful for their sexual health may offer an ideal opportunity to reach women at risk for HIV and to enhance their PrEP uptake and adherence. These services include those of family planning (FP) providers in high HIV incidence settings. However, PrEP has not been widely integrated into FP services, including Title X-funded FP clinics that provide safety net sources of care for AYAW. To overcome potential implementation challenges for AYAW, Title X clinics in the Southern United States are uniquely positioned to be focal sites for conceptually informed and thoroughly evaluated PrEP implementation science studies. OBJECTIVE: The aim of this study is to assess inner and outer context factors (barriers and facilitators) that may influence the adoption of PrEP prescription and treatment services in Title X clinics serving AYAW in the Southern United States. METHODS: Phase 1 of Planning4PrEP is an explanatory sequential, mixed methods study consisting of a geographically-targeted Web-based survey of Title X clinic administrators and providers in the Southern United States, followed by key informant interviews among a purposively selected subset of responders to more comprehensively assess inner and outer context factors that may influence adoption and implementation of PrEP in Title X FP clinics in the South. RESULTS: Phase 1 of Planning4PrEP research activities began in October 2017 and are ongoing. To date, survey and key informant interview administration is near completion, with quantitative and qualitative data analysis scheduled to begin soon after data collection completion. CONCLUSIONS: This study seeks to assess inner and outer contextual factors (barriers and facilitators) that may influence the adoption and integration of PrEP prescription and treatment services in Title X clinics serving AYAW in the Southern United States. Data gained from this study will inform a type 1 hybrid effectiveness implementation study, which will evaluate the multilevel factors associated with successful PrEP implementation while evaluating the degree of PrEP uptake, continuation, and adherence among women seen in Title X clinics. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/12774.
背景:美国南部的黑人青少年及年轻成年女性(AYAW)受艾滋病毒影响的比例过高。暴露前预防(PrEP)是一种有效、可扩展且由个人控制的艾滋病毒预防策略,但在所有年龄段的女性中都未得到充分利用,需要创新的提供方式来优化其效益。将PrEP的提供与AYAW已经信任、经常使用且认为对其性健康有益的卫生服务相结合,可能为接触艾滋病毒风险女性并提高她们对PrEP的接受度和依从性提供理想机会。这些服务包括艾滋病毒高发病率地区的计划生育(FP)提供者提供的服务。然而,PrEP尚未广泛纳入FP服务,包括为AYAW提供安全网护理来源的由第十类计划资助的FP诊所。为了克服AYAW在实施方面可能面临的挑战,美国南部的第十类诊所具有独特的地位,可成为进行概念清晰且经过充分评估的PrEP实施科学研究的重点场所。 目的:本研究旨在评估可能影响美国南部为AYAW服务的第十类诊所采用PrEP处方和治疗服务的内部和外部背景因素(障碍和促进因素)。 方法:“规划PrEP”的第一阶段是一项解释性序列混合方法研究,包括对美国南部第十类诊所管理人员和提供者进行基于网络的、按地理位置定向的调查,随后对有目的选择的一部分受访者进行关键信息访谈,以更全面地评估可能影响南部第十类FP诊所采用和实施PrEP的内部和外部背景因素。 结果:“规划PrEP”研究活动的第一阶段于2017年10月开始,仍在进行中。迄今为止,调查和关键信息访谈管理工作已接近完成,定量和定性数据分析计划在数据收集完成后不久开始。 结论:本研究旨在评估可能影响美国南部为AYAW服务的第十类诊所采用和整合PrEP处方及治疗服务的内部和外部背景因素(障碍和促进因素)。从本研究中获得的数据将为一项1型混合有效性实施研究提供信息,该研究将评估与PrEP成功实施相关的多层次因素,同时评估在第十类诊所就诊的女性中PrEP的接受度、持续率和依从性。 国际注册报告识别码(IRRID):DERR1-10.2196/12774。
BMJ Sex Reprod Health. 2023-7
MMWR Morb Mortal Wkly Rep. 2018-10-19
Clin Infect Dis. 2019-1-1
J Acquir Immune Defic Syndr. 2018-2-1
Ann Epidemiol. 2017-4
J Virus Erad. 2016-7-1